Why is Humira so expensive?

How much does a 30-day supply of Humira cost?

The list price (wholesale acquisition cost) for a 30-day supply of Humira (typically two 40-milligram pens) is approximately $7,000 to $9,000.

However, few people pay the full list price. The actual amount a person pays depends on their insurance coverage, pharmacy benefit manager (PBM) agreements, and eligibility for patient assistance programs.

• With commercial insurance: Many patients use the Humira Complete savings card, which may reduce out-of-pocket costs to as little as $5 per month.
• With Medicare or Medicaid: Costs vary significantly based on the specific plan and coverage stage (such as the “donut hole” or catastrophic coverage).
• Uninsured: Those without insurance may be responsible for the full list price unless they qualify for the myAbbVie Assist program.

It’s important to note that by 2026, many major insurance providers have begun removing brand-name Humira from their preferred drug lists (formularies) in favor of lower-cost alternatives, which may increase the cost for patients who choose to stay on the brand-name version.

Why does Humira cost so much?

There are several factors contributing to the high cost of Humira.

Complexity of biologics

Unlike traditional drugs which are made using chemical processes, Humira is a biologic. It’s a protein grown in living cell cultures. The manufacturing process is highly complex, sensitive, and expensive, requiring strict temperature controls and specialized facilities.

Research and development

AbbVie, the manufacturer, has invested billions of dollars into the clinical trials required to gain Food and Drug Administration (FDA) approval for Humira’s many indications (the conditions it’s used to treat). Pharmaceutical companies often cite these high research and development costs as a primary reason for high launch prices.

The patent thicket

One of the most criticized reasons for Humira’s sustained high price is what experts call a “patent thicket.” AbbVie filed over 130 patents related to Humira. These covered not just the drug itself, but its manufacturing process, dosing schedules, and even the injector device. This strategy successfully delayed competition in the United States for nearly 20 years.

Market exclusivity and rebates

Until 2023, Humira had no direct competition in the U.S. Even after competitors arrived, AbbVie utilized rebate traps, offering deep discounts to insurance companies and PBMs on the condition that they kept Humira as the preferred drug. This made it difficult for cheaper alternatives to gain market share.

Is there a cheaper alternative to Humira?

Yes. There are now several available biosimilars that are highly similar to Humira but cost significantly less. (A biosimilar is to a biologic what a generic is to a brand-name chemical drug, which means it has no clinically meaningful differences in terms of safety or effectiveness but tends to cost less.)

The following table shows some of the most common Humira alternatives in 2026 as well as websites and phone numbers for their financial assistance programs.

Interchangeable biosimilars

A key development is the “interchangeable” designation. An interchangeable biosimilar (such as Cyltezo or certain versions of Hadlima) can be substituted for Humira by a pharmacist without a new prescription from a doctor, similar to how a pharmacist swaps brand-name Lipitor for generic atorvastatin.

These alternatives can cost 50% to 80% less than the Humira list price.

When will there be a generic version of Humira?

Technically, there will never be a generic version of Humira. Because biologics are made from living cells, it’s impossible to create an exact identical copy.

However, the biosimilars mentioned above serve the same purpose as generics. While the first biosimilars were approved by the FDA as early as 2016, legal settlements delayed their entry into the U.S. market until January 2023.

As of 2026, more than 10 biosimilar versions of adalimumab are available on the U.S. market, providing the competition necessary to eventually drive down prices for patients and the healthcare system.

Takeaway

Humira remains expensive due to its biological complexity and the extensive patent protections that prevented competition for decades. While the list price remains high, the arrival of numerous biosimilar alternatives in 2023 and 2024 has finally created a path toward lower costs.

Patients concerned about the cost of Humira should speak with their doctor or pharmacist about switching to an interchangeable biosimilar or checking their 2026 insurance formulary for preferred, lower-cost options.